Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.01 from other evidence | 0.00 |
| cell type Human Protein Atlas | expressed broadly, no clear home in brain cells | 0.40 |
| chemistry Open Targets | hard to drug | 0.00 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | 1 Parkinson's papers of 35 | 0.91 |
| pathways Reactome | in no curated pathway | 0.00 |
No case: the score is under the bar. Receipt 8792
Sealed predictions
- DDX56 in dopamine neurons, braak+0.06 (p 0.875) → +0.21 (p 0.586)receipt 8799
Swarm cases
receipt 8799: DDX56 in dopamine neurons, braak
- power
- full sample +0.13 (p 0.609, n 18), 95% CI -0.36 to +0.56. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: +0.10 (p 0.683, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.08 (p 0.767, n 18). could be the mix.
- skeptic
- leave-one-out range +0.01 to +0.23, sign flips 0; without severely affected donors +0.13 (p 0.609, n 18). fragile.
- cell type
- strongest in astrocytes: -0.63 (p 0.0051, n 18) vs +0.13 in dopamine neurons. proposing astrocytes.
- axis
- no measure beats "tracks Braak Lewy-body stage" for DDX56 in dopamine neurons.
follow-up registered; not confirmed in substantia nigra, an independent cohort.
follow-up DDX56 · astrocytes · braak: substantia nigra, an independent cohort (Parkinson's or LBD vs controls) +0.25 p 0.374 (needs p < 2.4e-4)
Receipts
loading the receipts